Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 20 04:00PM ET
14.90
Dollar change
+1.39
Percentage change
10.29
%
IndexRUT P/E- EPS (ttm)-3.55 Insider Own30.34% Shs Outstand45.99M Perf Week8.44%
Market Cap756.37M Forward P/E- EPS next Y-4.01 Insider Trans-0.08% Shs Float32.06M Perf Month-5.82%
Income-154.14M PEG- EPS next Q-0.96 Inst Own81.28% Short Float17.63% Perf Quarter-23.51%
Sales0.00M P/S- EPS this Y77.73% Inst Trans9.59% Short Ratio20.77 Perf Half Y-4.30%
Book/sh8.72 P/B1.71 EPS next Y-8.88% ROA-57.80% Short Interest5.65M Perf Year-19.98%
Cash/sh7.98 P/C1.87 EPS next 5Y- ROE-69.81% 52W Range12.17 - 33.92 Perf YTD-35.64%
Dividend Est.- P/FCF- EPS past 5Y- ROI-35.90% 52W High-56.07% Beta2.73
Dividend TTM- Quick Ratio18.95 Sales past 5Y0.00% Gross Margin- 52W Low22.43% ATR (14)1.49
Dividend Ex-Date- Current Ratio18.95 EPS Y/Y TTM- Oper. Margin- RSI (14)43.08 Volatility13.14% 8.90%
Employees- Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price31.38
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q-2.14% Payout- Rel Volume3.80 Prev Close13.51
Sales Surprise- EPS Surprise20.62% Sales Q/Q- EarningsNov 12 AMC Avg Volume272.08K Price14.90
SMA20-7.85% SMA50-19.73% SMA200-22.03% Trades Volume1,033,254 Change10.29%
Date Action Analyst Rating Change Price Target Change
Nov-26-24Initiated William Blair Outperform
Jul-22-24Initiated H.C. Wainwright Buy $33
Jul-08-24Initiated Chardan Capital Markets Buy $28
Jun-27-24Initiated Piper Sandler Overweight $37
Dec-05-23Initiated Truist Buy $34
Dec-05-23Initiated TD Cowen Outperform
Dec-05-23Initiated JP Morgan Overweight $23
Dec-05-23Initiated Jefferies Buy $28
Dec-17-24 08:00AM
Dec-16-24 06:34PM
Dec-12-24 09:55AM
Nov-12-24 04:05PM
Nov-05-24 04:05PM
09:23AM Loading…
09:23AM
Aug-16-24 08:53PM
06:50PM
Aug-12-24 04:05PM
Jul-10-24 08:00AM
Jun-04-24 04:05PM
01:56PM
May-30-24 06:00AM
May-28-24 08:05AM
08:00AM
12:00PM Loading…
May-22-24 12:00PM
09:55AM
May-14-24 09:54PM
04:05PM
Apr-15-24 04:05PM
Mar-21-24 10:53PM
04:05PM
Feb-29-24 04:01PM
Jan-03-24 08:05AM
Dec-18-23 04:04PM
Dec-13-23 10:51PM
04:05PM
Dec-11-23 07:53PM
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Carlos, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chapman GinaPresident & CEOSep 18 '24Option Exercise5.037,16636,045111,071Sep 20 05:24 PM
Chapman GinaPresident & CEOSep 19 '24Option Exercise5.032,97514,964106,880Sep 20 05:24 PM
Chapman GinaPresident & CEOSep 18 '24Sale25.097,166179,775103,905Sep 20 05:24 PM
Chapman GinaPresident & CEOSep 19 '24Sale25.032,97574,457103,905Sep 20 05:24 PM
Radhakrishnan AnupChief Financial OfficerSep 18 '24Option Exercise5.031,6008,0488,046Sep 20 05:23 PM
Radhakrishnan AnupChief Financial OfficerSep 18 '24Sale25.281,60040,4526,446Sep 20 05:23 PM
ANUP RADHAKRISHNANOfficerSep 18 '24Proposed Sale23.3314,000326,620Sep 18 04:38 PM
GINA CHAPMANDirectorSep 18 '24Proposed Sale23.3375,0001,749,750Sep 18 04:36 PM
Samsara BioCapital GP, LLC10% OwnerMay 30 '24Buy17.00294,0004,998,0004,415,689Jun 03 09:45 PM